Analgesia in the Critically Ill: Delivering, Monitoring, and Mastering the Art of Pain Control in the ICU

Dr Neeraj Manikath , claude.ai

---

"The patient lay sedated and apparently still — heart rate 112, blood pressure 158/96. The nurse noted she had not moved in six hours. Her family said she was 'comfortable.' Her CPOT score was 6. She was in agony. We had sedated the witness, not the pain."

— ICU Grand Rounds, Teaching Case, 2023

---

Introduction: The Invisible Epidemic Within Our ICUs

Pain is the most common, most undertreated, and most consequential symptom experienced by patients in the intensive care unit. Epidemiological data from the multinational EUROPATIENT study and subsequent registries consistently demonstrate that up to 80% of ICU patients experience moderate-to-severe pain, yet fewer than half receive adequate analgesia. The landmark ABCDEF Bundle trials and the 2018 PADIS (Pain, Agitation/Sedation, Delirium, Immobility, and Sleep) guidelines from the Society of Critical Care Medicine (SCCM) have fundamentally repositioned our thinking: pain, not sedation, must be addressed first.

The consequences of undertreated pain extend far beyond humanitarian concern. Poorly controlled pain activates the hypothalamic-pituitary-adrenal axis and the sympathoadrenal system, precipitating tachycardia, hypertension, increased myocardial oxygen demand, immune suppression, hypercoagulability, and impaired wound healing. Longitudinally, it contributes to post-intensive care syndrome (PICS), post-traumatic stress disorder (PTSD), and chronic pain syndromes — a burden that follows patients well beyond hospital discharge. Pain management in the ICU is not a comfort measure. It is a mortality-relevant intervention.

---

Pathophysiology: Only What You Must Know at the Bedside

Understanding why pain in the critically ill is biologically unique helps explain why standard analgesic approaches frequently fail.

Peripheral and central sensitisation occur rapidly in the setting of surgery, trauma, sepsis, and tissue ischaemia. Inflammatory mediators — prostaglandins, bradykinin, substance P, and cytokines — lower the firing threshold of nociceptors (peripheral sensitisation), while repeated nociceptive input leads to synaptic strengthening in the dorsal horn of the spinal cord (central sensitisation). The clinical result is allodynia (pain from non-painful stimuli) and hyperalgesia (exaggerated pain from noxious stimuli) — phenomena that render standard analgesic doses profoundly inadequate.

Critical illness additionally disrupts opioid pharmacokinetics in predictable ways: altered volume of distribution from capillary leak and third-spacing, impaired hepatic metabolism in multi-organ dysfunction, and reduced renal clearance of active metabolites. This creates a paradox — the sicker the patient, the less predictable the drug behaviour, and the more vigilant the monitoring must be.

Procedural pain deserves special mention. Studies using objective pain tools demonstrate that endotracheal suctioning, repositioning, wound care, and arteriovenous line insertion are among the most painful interventions in the ICU — more painful, for many patients, than the underlying illness. These "routine" care activities are a source of acute procedural pain that is systematically under-recognised and under-medicated.

---

🪙 Clinical Pearls

Pearl 1 — Sedation Masquerades as Comfort A deeply sedated patient who does not grimace is not a pain-free patient. Sedatives suppress the expression of pain, not the experience of it. The CPOT (Critical-care Pain Observation Tool) was specifically designed for non-communicative patients and captures facial expressions, body movements, muscle tension, and ventilator compliance — scoring ≥3 mandates analgesia regardless of apparent stillness.

Pearl 2 — Opioid Requirement is Diagnostic If a mechanically ventilated patient suddenly requires escalating fentanyl, before increasing the dose — pause. Consider pneumothorax, ET tube displacement, worsening pulmonary oedema, or peritoneal contamination. Pain behaviour is a clinical sign, not just a complaint.

Pearl 3 — The Hyperalgesia Trap Prolonged high-dose opioid infusions paradoxically increase pain sensitivity (opioid-induced hyperalgesia, OIH). A patient on Day 7 of morphine infusion who appears to require ever-increasing doses may actually be experiencing OIH — adding more morphine worsens the problem. Rotating to a different opioid (e.g., hydromorphone) or using low-dose ketamine is the solution.

Pearl 4 — Renal Failure and Morphine: A Hidden Killer Morphine-6-glucuronide (M6G) — the pharmacologically active metabolite of morphine — accumulates dangerously in renal failure, causing prolonged and life-threatening respiratory depression hours after the last dose. Fentanyl is the opioid of choice in AKI and CKD because it lacks active accumulating metabolites.

---

🦪 Oysters: Hidden Gems Most Clinicians Miss

Oyster 1 — The "Analgesia-First" or "Analgosedation" Paradigm Most intensivists still reach for propofol or midazolam first when a patient is agitated. The 2018 PADIS guidelines explicitly recommend analgesia-first sedation — treating pain before adding sedatives. In trials, this approach reduced sedative requirements, duration of mechanical ventilation, and ICU length of stay. Remifentanil-based analgosedation protocols have consistently outperformed traditional sedation approaches in this regard.

Oyster 2 — Ketamine: The Most Underused Analgesic in Critical Care Ketamine at sub-anaesthetic doses (0.1–0.5 mg/kg/hr as an infusion) provides excellent analgesia via NMDA receptor antagonism, preserves respiratory drive, reduces opioid consumption by 30–40%, and counteracts opioid-induced hyperalgesia. Yet it remains woefully underused. The 2022 KEAT (Ketamine Effectiveness as Analgesic Therapy) trial confirmed its opioid-sparing role without significant haemodynamic instability. It should be part of every intensivist's multimodal toolkit — particularly in post-surgical and trauma patients.

Oyster 3 — Regional Anaesthesia Has an ICU Role Thoracic epidural analgesia (TEA) in post-operative thoracic and abdominal surgical patients, transversus abdominis plane (TAP) blocks, and erector spinae plane (ESP) blocks are increasingly being deployed by anaesthesiologists and trained intensivists in the ICU. These techniques dramatically reduce opioid consumption, improve respiratory mechanics, and facilitate earlier extubation — yet are rarely considered once the patient has left the operating theatre.

Oyster 4 — The Circadian Rhythm of Pain Pain thresholds vary by time of day; most ICU patients report worst pain between 2:00 AM and 6:00 AM, during nursing procedures performed with reduced staffing. Timed analgesic adjustments — a concept borrowed from oncology palliative care — have not been formally studied in the ICU but represent an area of practice that master clinicians intuitively address.

Oyster 5 — Gabapentinoids for Neuropathic Pain Components Up to 30% of post-cardiac surgery, post-trauma, and prolonged ICU patients develop a neuropathic pain component characterised by burning, lancinating, or electric-shock quality pain. Opioids address this poorly. Low-dose gabapentin (100–300 mg BD, renally adjusted) or pregabalin is effective, but requires careful dose reduction for renal function and vigilance for respiratory depression when co-administered with opioids or benzodiazepines.

---

⚡ Clinical Hacks & Tips: What Master Intensivists Actually Do

Hack 1 — Build a Pain Round into Your Ward Round Structured morning pain assessment using the NRS (Numerical Rating Scale, 0–10) in communicative patients, or CPOT in non-communicative patients, should be as routine as reviewing ventilator settings. The target is NRS ≤3 or CPOT <3. Document this explicitly; it drives analgesic titration.

Hack 2 — Anticipate Procedural Pain: Pre-medicate, Don't React For every scheduled painful procedure (suctioning, chest physiotherapy, repositioning, line insertions, wound care), administer a short-acting opioid 15–30 minutes before the procedure. Fentanyl 25–50 mcg IV is ideal — rapid onset (2–3 min), predictable duration (30–45 min), easy to titrate.

Hack 3 — The Multimodal Analgesic Stack Avoid opioid monotherapy. Build a stack:

Layer	Drug	Typical Dose	Rationale
Base	Paracetamol (IV/oral)	1g q6h	Synergistic, opioid-sparing
Anti-inflammatory	IV ibuprofen or ketorolac	Ketorolac 15–30 mg q6h (max 5 days)	Use cautiously; avoid in AKI/GI bleed
Neuropathic	Gabapentin / Pregabalin	100–300 mg BD (renal-adjusted)	For neuropathic component
Procedural/acute	Fentanyl IV bolus	25–50 mcg PRN	Short-acting, titratable
Opioid maintenance	Morphine/Fentanyl infusion	Titrate to CPOT <3	Avoid morphine in AKI
NMDA adjunct	Ketamine infusion	0.1–0.3 mg/kg/hr	OIH prevention, opioid-sparing

Hack 3 — Delirium and Pain: Treat the Pain First Hyperactive delirium frequently coexists with undertreated pain. Before labelling a patient as delirious and administering antipsychotics or benzodiazepines, ensure adequate analgesia. Pain and delirium have a bidirectional, self-reinforcing relationship — breaking the pain cycle often dramatically reduces delirium severity.

Hack 4 — When Converting Between Opioids, Use Equianalgesic Tables and Reduce by 25–30% Incomplete cross-tolerance means that when rotating opioids, the equianalgesic dose will often exceed what is required. Standard practice is to calculate the equianalgesic dose, then reduce by 25–30% to avoid inadvertent overdose, and then titrate up as needed.

---

State-of-the-Art Updates: What Has Changed Practice

1. PADIS 2018 Guidelines — The Framework Shift The landmark 2018 SCCM PADIS guidelines formally established the priority order: Analgesia → Sedation → Delirium management. They endorsed CPOT and BPS (Behavioural Pain Scale) as validated tools for non-communicative, mechanically ventilated patients and made analgesia-first sedation a Grade 2B recommendation.

2. The SPICE III Trial (2019) This landmark RCT comparing early sedation with dexmedetomidine versus usual care demonstrated no mortality benefit for dexmedetomidine — but did confirm that lighter sedation is safe and associated with faster weaning. Dexmedetomidine remains valuable for its opioid-sparing, anti-shivering, and delirium-mitigating properties rather than as a primary analgesic.

3. Low-Dose Ketamine in Post-Operative ICU Patients Multiple RCTs and meta-analyses from 2020–2024 confirm that subanesthetic ketamine infusions (0.1–0.5 mg/kg/hr) reduce 24-hour opioid consumption by 30–40%, without significant increases in hallucinations or haemodynamic instability when used at these doses. This is now an ERAS (Enhanced Recovery After Surgery) recommendation in several major guidelines.

4. Point-of-Care Ultrasound-Guided Nerve Blocks in ICU The evolution of bedside POCUS has empowered trained intensivists to perform real-time guided nerve blocks (TAP, ESP, femoral, popliteal sciatic) at the bedside. A 2023 systematic review confirmed significant reductions in opioid requirements and improved respiratory mechanics with ESP blocks in rib fracture patients.

5. Non-Opioid Analgesics for Critically Ill — IV Lidocaine Intravenous lidocaine infusion (1.5 mg/kg bolus followed by 1.5 mg/kg/hr) has emerged as an evidence-based opioid-sparing analgesic in post-operative ICU patients, particularly following abdominal surgery. A 2022 Cochrane review confirmed significant opioid-sparing, anti-inflammatory, and prokinetic benefits. Cardiac monitoring is mandatory.

---

Diagnostic Nuances: Separating Good from Great Clinicians

The Non-Communicative Patient Intubated, sedated, or cognitively impaired patients cannot self-report pain — the gold standard. This is where most analgesic failures occur. Validated behavioural tools are mandatory:

• CPOT (Critical-care Pain Observation Tool): Scores 4 domains — facial expression, body movements, muscle tension, ventilator compliance. Score ≥3 = significant pain. Validated in multiple ICU populations.
• BPS (Behavioural Pain Scale): Similar construct; particularly validated in post-surgical patients.
• Pupillometry: The Nociception Level (NOL) index, derived from multiparameter pupillometric analysis, is an emerging continuous, objective pain monitor — not yet standard of care, but increasingly available in tertiary centres.

The Delirious Patient Agitation and delirium are frequently misinterpreted as psychiatric in origin, when they are often pain-driven. Use CAM-ICU for delirium detection; if delirium coexists with high CPOT scores, treat pain first and reassess.

Signs of Opioid Toxicity in the Monitored ICU Patient

• Respiratory rate <10 breaths/min in a spontaneously breathing patient
• Miosis with reduced SpO2
• Sudden improvement in agitation followed by reduced GCS
• End-tidal CO2 rise on capnography (in monitored patients)

Withdrawal Mimicking Undertreated Pain Patients who have received opioids for ≥5–7 days are at risk for opioid withdrawal when weaning. Withdrawal presents with tachycardia, hypertension, diaphoresis, lacrimation, GI upset, and agitation — all of which can masquerade as undertreated pain and trigger unwarranted dose escalation. Planned, structured opioid weaning protocols (typically 10–20% dose reduction every 24–48 hours) prevent this.

---

Management Intricacies: Drugs, Doses, Timing, and Pitfalls

Opioids — The Backbone, Not the Whole House

Opioid	Onset IV	Duration	Key Points
Fentanyl	2–3 min	30–60 min	Drug of choice in AKI; no histamine release
Morphine	5–10 min	3–4 hr	Avoid in AKI (M6G accumulation); cheap, familiar
Hydromorphone	5 min	3–4 hr	5–7x potency of morphine; use in opioid-tolerant patients
Remifentanil	<1 min	5–10 min	Ultra-short; ideal for analgosedation protocols; context-insensitive
Methadone	10–15 min	24–36 hr	QTc prolongation risk; complex kinetics; use for opioid rotation/weaning

Non-Opioid Multimodal Agents — Never Optional

• Paracetamol (IV): 1g q6h — the cornerstone of multimodal analgesia. Opioid-sparing effect of 20–30%. Safe in hepatically normal patients. Do not omit.
• NSAIDs/Ketorolac: Significant opioid-sparing but contraindicated in AKI, GI haemorrhage, coagulopathy, and post-cardiac surgery. If using, limit to 5 days maximum.
• Dexmedetomidine: Alpha-2 agonist with sedative and opioid-sparing properties. Particularly valuable post-extubation for analgo-sedation. Does not cause respiratory depression. Monitor for bradycardia and hypotension.

Titration Principles

• In mechanically ventilated patients: Titrate to CPOT <3. Do not use a fixed infusion dose without regular reassessment.
• In spontaneously breathing patients: NRS ≤3. Reassess every 4 hours.
• Daily sedation interruption (DSI) with concurrent pain assessment during the "window" is mandated by international guidelines — but ensure analgesic coverage is maintained during and after DSI.

---

When to Escalate / When to Watch

Escalate if:

• CPOT ≥3 or NRS >6 despite optimised multimodal analgesia
• Haemodynamic instability (tachycardia, hypertension) in context of high behavioural pain scores
• Patient is requiring >2 analgesic rescue doses per shift
• Signs of opioid inadequacy: patient is distressing, desynchronising with ventilator, actively resisting care

Watch and reassess if:

• CPOT 3–4 with single-agent therapy — implement multimodal stack before escalating opioids
• Post-procedural pain likely to be transient (<30 minutes) — give short-acting agent and monitor
• Suspected OIH — reduce opioid, add ketamine, reassess

De-escalate when:

• CPOT consistently <3 for >12–24 hours
• Patient is tolerating oral medications — transition to oral opioids with overlap
• Ready for structured opioid weaning protocol (≥5 days on infusion)

---

Memorable Summary: The A-PAIN Framework

Letter	Domain	Key Action
A	Assess First	CPOT / BPS for non-verbal; NRS for verbal. Every shift. Every round.
P	Pain Before Sedation	Analgesia-first (analgosedation). Never sedate an unanalgesed patient.
A	Anticipate Procedure	Pre-medicate 15 min before every painful procedure.
I	Individualise & Rotate	Choose opioid based on renal function. Rotate if OIH suspected.
N	Non-opioid Stack	Paracetamol + ketamine + regional techniques. Opioids are one layer, not all layers.

Mnemonic: STOP Pain S — Score it (CPOT/NRS) T — Treat it (multimodal, not opioid-only) O — Observe for side effects (respiratory depression, OIH, withdrawal) P — Plan the wean (structured taper, not abrupt cessation)

---

References (Vancouver Style)

1. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.

2. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.

3. Gélinas C, Fillion L, Puntillo KA, et al. Validation of the Critical-Care Pain Observation Tool in adult patients. Am J Crit Care. 2006;15(4):420–427.

4. Chanques G, Viel E, Constantin JM, et al. The measurement of pain in intensive care unit: Comparison of 5 self-report intensity-rating scales. Pain. 2010;151(3):711–721.

5. Olsen BF, Rustøen T, Sandvik L, et al. Prevalence of pain in intensive care unit patients: Linked to patient and intensive care factors. Nurs Crit Care. 2016;21(6):364–372.

6. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill patients (SPICE III): A randomised controlled trial. Lancet. 2019;394(10208):1537–1548.

7. Peng K, Liu HY, Liu SL, et al. Ketamine as an adjunct to intravenous patient-controlled analgesia following hip arthroplasty: A systematic review and meta-analysis. Pain Pract. 2022;22(2):175–187.

8. Grape S, Kirkham KR, Frauenknecht J, et al. Intra-operative analgesia with remifentanil vs. dexmedetomidine: A systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(6):793–800.

9. Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: Pharmacological and clinical aspects of ketamine and gabapentinoids. Pharmacol Res. 2012;65(4):411–429.

10. Gélinas C, Chanques G, Puntillo K. In pursuit of pain: Recent advances and future directions in pain assessment in the ICU. Curr Opin Crit Care. 2014;20(2):131–137.

11. Olkowski BF, Shah SO. Early Mobilization in the Neuro-ICU: How Far Can We Go? Neurocrit Care. 2017;27(1):141–150.

12. Puntillo K, Arai SR, Cooper BA, et al. A randomized clinical trial of an intervention to relieve thirst and dry mouth in intensive care unit patients. Intensive Care Med. 2014;40(9):1295–1302.

13. Moline J, Temkin-Greener H. ICU pain management: Time to embrace multimodal analgesia. J Crit Care. 2021;62:250–254.

14. Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of systemic alpha2 agonists on postoperative morphine consumption and pain intensity: Systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312–1322.

15. Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: A review. JAMA Surg. 2017;152(7):691–697.

---

Correspondence: Author available for postgraduate teaching sessions and CME programme collaboration. Views expressed represent the author's academic interpretation of current evidence; clinical decisions should be individualised.

---

Word count: ~2,200 

Delirium Tremens, Hepatic Encephalopathy, and the Treacherous Mixed State: A Clinician's Guide to Differentiation and Treatment

 

GRAND ROUNDS REVIEW

Delirium Tremens, Hepatic Encephalopathy, and the Treacherous Mixed State: A Clinician's Guide to Differentiation and Treatment

Dr Neeraj Manikath , claude.ai

1. Clinical Introduction

 

🏥  Clinical Vignette •      A 48-year-old man with a background of alcohol use disorder (AUD) and Child–Pugh B cirrhosis is admitted via the emergency department following a witnessed generalised tonic-clonic seizure. His wife reports that he consumed approximately 180 g of alcohol daily until three days ago, when he abruptly stopped drinking after developing abdominal distension and jaundice. •      On arrival: GCS 12/15 (E3V4M5), temperature 38.6°C, heart rate 128 bpm, BP 168/96 mmHg, diaphoretic, tremulous. He is agitated and hallucinating — reporting insects on the wall. Examination reveals a flapping tremor (asterixis), scleral icterus, a moderately tender hepatomegaly, and shifting dullness. Labs show: ALT 214 U/L, bilirubin 84 μmol/L, albumin 26 g/L, INR 1.9, ammonia 92 μmol/L, sodium 128 mmol/L, and blood glucose 3.4 mmol/L. •      Is this delirium tremens? Hepatic encephalopathy? Or — most dangerously — both at once?

 

Alcohol use disorder affects over 280 million people worldwide, and approximately 5–10% of those who abruptly stop drinking will develop delirium tremens (DT) — the most severe form of alcohol withdrawal syndrome (AWS), carrying an untreated mortality of up to 37%. Yet for the large cohort of patients who also carry advanced liver disease, a second and equally life-threatening syndrome lurks: hepatic encephalopathy (HE). Crucially, both syndromes can coexist — the so-called "mixed state" — and misdiagnosis or mismanagement of either has lethal consequences. Benzodiazepines, the cornerstone of DT treatment, can precipitate or worsen HE. Conversely, withholding them in true DT out of fear of hepatic decompensation is equally dangerous. This review equips the clinician with the tools to navigate this diagnostic minefield.

 

2. Pathophysiology — Only What You Need at the Bedside

Delirium Tremens

Chronic alcohol use upregulates excitatory NMDA glutamate receptors and downregulates inhibitory GABA-A receptors — a neuroadaptive response to the sedating effects of alcohol. Abrupt cessation unmasks a state of CNS hyperexcitability: unchecked glutamatergic drive produces the clinical picture of agitation, tremor, seizures, autonomic storms, and hallucinations. The peak period of DT is 48–96 hours after the last drink, though onset up to 7–10 days is documented, particularly in hospitalised patients given inadvertent sedation.

Hepatic Encephalopathy

HE is fundamentally a neuroinflammatory disorder driven by systemic accumulation of gut-derived toxins — principally ammonia — through a failing hepatic filter. Hyperammonaemia causes astrocyte swelling (Alzheimer type II changes), impairs the blood-brain barrier, and augments GABAergic tone — paradoxically mimicking some features of AWS. Superimposed inflammation (infection, SIRS) dramatically amplifies the neurotoxic effect. Critically, ammonia alone does not explain all of HE; the gut microbiome, zinc deficiency, neurosteroids, and inflammatory cytokines all contribute.

The Mixed State — Why It Is So Dangerous

In patients with AUD and cirrhosis, both pathways operate simultaneously. The withdrawal-driven NMDA upregulation competes against the ammonia-driven GABA augmentation — producing a variable and clinically unpredictable phenotype. Autonomic instability (which in DT reflects withdrawal) may be masked by the haemodynamic vasodilation of portal hypertension. Seizures — a red flag for DT — may be absent because HE-driven GABAergic tone provides partial suppression. Treatment with benzodiazepines (BZDs) may initially improve DT features but paradoxically worsen encephalopathy. This is the most treacherous clinical scenario in alcohol-related liver disease.

 

3. Clinical Pearls 🪙

🪙  High-Yield Bedside Observations •      The timing of the last drink is everything — DT virtually never starts <6 hours after last drink; if delirium begins at presentation, think HE, sepsis, or Wernicke's first. •      Autonomic storm (HR >120, diaphoresis, hypertension, fever >38.5°C) strongly favours DT over HE. HE rarely causes sustained hypertension — if BP is high, treat DT. •      Asterixis (flapping tremor) is the hallmark of HE but can be subtle; always test both hands with wrists dorsiflexed and eyes closed for ≥15 seconds. Absence does not rule out HE. •      A normal ammonia does not exclude HE — specimen handling artefact is common. Always request ice-cold plasma ammonia and process within 15 minutes. •      Do not anchor on one diagnosis: a GCS falling despite BZD loading must prompt urgent reassessment for HE, Wernicke's encephalopathy, or hypoglycaemia. •      The CIWA-Ar was not validated in patients with hepatic encephalopathy — its scores may be falsely elevated in HE and lead to BZD overload. Use it with caution and clinical context.

 

4. Oysters 🦪

🦪  Hidden Gems Most Clinicians Miss •      Wernicke's encephalopathy is a third wheel: the classic triad (ophthalmoplegia, ataxia, confusion) is present in <20% of cases. In any patient with AUD and delirium, give IV thiamine 500 mg TDS for at least 3 days — never wait for the triad, never give dextrose first. •      Spontaneous bacterial peritonitis (SBP) is a silent DT precipitant — it can worsen HE through systemic inflammation while simultaneously masking DT's autonomic features. Always perform a diagnostic paracentesis in the cirrhotic patient presenting with altered consciousness, even without abdominal pain. •      Hyponatraemia in cirrhosis blunts the hyperexcitability of withdrawal — DT features may be attenuated in patients with Na <125 mmol/L, leading to false reassurance. Do not lower the CIWA-Ar threshold based on sedate appearance. •      Phenobarbital may be the unsung hero of the mixed state: unlike BZDs, it provides GABAergic sedation via a distinct receptor site with lower respiratory depression risk in titrated doses, and does not disinhibit hepatic encephalopathy as dramatically. •      Alcohol use disorder predisposes to hypoglycaemia through inhibition of gluconeogenesis — always check glucose at presentation and hourly in the first 6 hours. Hypoglycaemia alone can cause agitation and tremor indistinguishable from DT.

 

5. Clinical Hacks & Tips ⚡

⚡  Practical Shortcuts from Master Clinicians •      The '3+3 Rule' for initial DT management: give 3 mg IV lorazepam (or diazepam 10 mg) every 5–10 minutes, up to 3 doses, monitoring respiratory rate — if still agitated after 9 mg lorazepam, move to ICU-level care and consider phenobarbital. •      Use propofol infusion in ventilated patients with refractory DT + HE: it provides GABAergic sedation, does not worsen ammonia, and allows titration without cumulative BZD loading. •      The 'CIWA clock' trick: restart the 24-hour CIWA-Ar clock whenever scores rise >10 — prolonged or relapsing courses predict complicated withdrawal needing HDU escalation. •      In the mixed state, target mild sedation (RASS -1 to 0) rather than deep sedation — over-sedation worsens HE while under-sedation risks DT seizures. •      Ask nursing staff about the 'quiet period' — a window of relative calm between alcohol seizures and DT is characteristic of AWS; absence of this window should raise suspicion for an alternative or additional diagnosis. •      Lactulose works best when it produces 2–3 soft stools per day — less is constipation (worsening HE), more is diarrhoea (electrolyte disaster). Titrate, not simply prescribe.

 

6. State-of-the-Art Updates

Symptom-triggered vs fixed-schedule BZD dosing: A pivotal RCT demonstrated that symptom-triggered lorazepam (guided by CIWA-Ar ≥8) significantly reduces total BZD dose and duration of treatment compared with fixed-schedule dosing without increasing complication rates. This is now standard of care — avoid fixed 4-hourly BZD regimens unless the patient cannot be reliably assessed.

Alpha-2 agonists as BZD-sparing adjuncts: Dexmedetomidine and clonidine are increasingly used to blunt sympathetic hyperactivation in DT, reducing BZD requirements without directly suppressing respiration. Dexmedetomidine is particularly useful in ICU-level DT but does not prevent seizures — it must never replace BZDs as monotherapy.

Rifaximin has transformed outpatient HE: Added to lactulose, rifaximin reduces recurrence of overt HE by >50% and is now guideline-recommended (AASLD/EASL 2014) for secondary prevention. In the inpatient mixed state, it can be started once the patient can swallow, but it does not replace lactulose acutely.

Microbiome modulation and LOLA (L-ornithine L-aspartate): Emerging evidence suggests LOLA reduces ammonia and improves HE grade compared with placebo, and may be particularly useful in HE patients who cannot tolerate lactulose. It is not yet universally guideline-endorsed but is gaining traction in European hepatology practice.

Fecal microbiota transplant (FMT) in HE: Early trials show benefit in recurrent HE refractory to standard therapy, and a landmark RCT by Bajaj et al. demonstrated cognitive and microbiome improvements post-FMT. This remains investigational but represents a genuine paradigm shift in understanding HE as a gut-brain axis disorder.

 

7. Diagnostic Nuances

History

Establish the exact time of last alcoholic drink — this single datum transforms risk stratification. Obtain collateral history from a reliable source. Ask specifically about prior episodes of DT or alcohol withdrawal seizures — "kindling" means each successive withdrawal episode may be more severe. Enquire about dietary intake, as prolonged starvation in alcoholism accelerates refeeding syndrome risk and Wernicke's.

Examination

The neurological examination should be meticulous and repeated. Pupillary dilation favours DT (sympathetic storm); miosis raises concern for opiate use, and normal-to-small pupils are more consistent with HE. The "liver flap" (asterixis) is best elicited with eyes closed, arms extended, and wrists maximally dorsiflexed — a negative test for 15 seconds provides reasonable exclusion. Check for nystagmus and ophthalmoplegia (Wernicke's); hepatic foeter (a sweetish musty breath) in HE; and parotid enlargement and Dupuytren's contracture as stigmata of chronic AUD.

Investigations

Beyond routine bloods, order: EEG — triphasic waves are characteristic of HE; low-voltage fast activity with theta waves predominates in DT. CT head should be performed early if there is focal neurology, head injury concern, or failure to improve. Ammonia (ice-cold plasma) is useful as a trend rather than absolute — a rising ammonia in a deteriorating patient is actionable. Procalcitonin and blood cultures are mandatory; infection is the most common HE precipitant and may simulate autonomic features of DT.

 

8. Management Intricacies

The Non-Negotiables — First Hour

Every patient with suspected DT, HE, or mixed state requires: (1) IV access and continuous monitoring; (2) blood glucose — treat hypoglycaemia immediately with 50% dextrose but only after thiamine; (3) thiamine 500 mg IV TDS — this is the single most important pharmacological intervention in AUD-related neurology; (4) IV fluids — normal saline first-line (avoid dextrose-containing fluids until glucose checked and thiamine given); (5) electrolyte correction — hypokalaemia, hypomagnesaemia, and hypophosphataemia are universal and perpetuate both DT and HE.

Treating Pure DT

Benzodiazepines remain first-line. IV lorazepam 2–4 mg every 5–10 minutes (symptom-triggered) is preferred in severe DT for its predictable pharmacokinetics. Diazepam (10–20 mg IV) exploits its long-acting active metabolites (desmethyldiazepam) for smoother blood levels but accumulates dangerously in hepatic failure — avoid diazepam in decompensated cirrhosis. In refractory DT (CIWA-Ar >20 despite 40 mg diazepam equivalent), use phenobarbital 130–260 mg IV with close respiratory monitoring, or intubate and use propofol infusion. Add dexmedetomidine 0.2–1.4 mcg/kg/h as an adjunct to reduce BZD requirements. Beta-blockers (propranolol, atenolol) blunt tachycardia but do not prevent seizures and should never be used as monotherapy.

Treating Pure HE

Identify and reverse the precipitant — this is as important as any drug. Common triggers (use the mnemonic TIPS: Toxins/drugs, Infection, Porto-systemic shunt, Spontaneous bleeding) should be systematically excluded. Lactulose 30–45 mL every 1–2 hours until 2–3 stools per day, then titrate. Rifaximin 550 mg BD for recurrence prevention. Correct protein malnutrition — do not restrict dietary protein; current EASL guidelines recommend 1.2–1.5 g/kg/day protein. Branched-chain amino acids (BCAAs) may be supplementary in those intolerant to standard protein. Zinc supplementation (220 mg BD) is underused but has trial evidence in HE.

The Mixed State — A Structured Protocol

Step 1: Treat the life-threatening condition first. If CIWA-Ar >20 with autonomic storm — treat DT first with lorazepam (preferred over diazepam in liver disease), using the lowest effective dose.

Step 2: Simultaneously initiate lactulose via NG tube if the patient is obtunded and cannot swallow. Avoid fleet enemas as first-line — they are useful in acute high-ammonia HE but cause electrolyte disturbance.

Step 3: When BZD requirement remains high (>20 mg diazepam equivalent in 24 h) in a patient with decompensated liver disease, transition to phenobarbital — it has less ammonia generation and less respiratory depression at therapeutic doses than escalating BZDs.

Step 4: Target RASS -1 to 0 (lightly sedated, arousable). Deeper sedation worsens HE and delays assessment. Haloperidol 2.5–5 mg IV/IM may be used for agitation not responsive to BZDs but carries QTc prolongation risk — check ECG first.

 

9. When to Escalate / When to Watch

🔴  Escalate to HDU/ICU — Act Now •      Recurrent seizures (≥2 in 6 hours) or status epilepticus •      CIWA-Ar >20 despite ≥40 mg diazepam equivalent in 4 hours •      Respiratory depression (RR <10) or SpO2 <92% in a spontaneously breathing patient on BZDs •      GCS ≤10 or rapidly declining consciousness •      Haemodynamic instability: SBP <90 mmHg or requiring vasopressors •      Acute liver failure superimposed on chronic disease (INR >2.5 + AKI + encephalopathy) — transplant evaluation pathway

 

🟢  Safe to Monitor on a Monitored Ward •      CIWA-Ar 8–15, responding to PRN lorazepam, no seizures •      HE Grade I–II with a clearly identified and addressable precipitant •      Stable haemodynamics, no respiratory compromise, electrolytes corrected •      Patient arousable, protecting airway, tolerating oral lactulose •      Hourly nursing observations with clear escalation triggers documented

 

10. Summary: The DRINK Mnemonic & Comparison Table

The DRINK Mnemonic — your bedside framework for every alcohol-related delirium:

 

Letter	Stands For	Clinical Action
D	Drinking history & Duration	Last drink time, quantity, prior DT/seizures
R	Rule out HE first	LFTs, ammonia, clinical flap — before loading BZDs
I	Investigate triggers	Infection, GI bleed, drugs, electrolytes, glucose
N	Neuro signs	Asterixis = HE; coarse tremor = DT; both = mixed
K	CIWA-Ar scoring	Score every 4–8 h; symptom-triggered dosing preferred
T	Thiamine — always first	500 mg IV TDS × 3 days before any dextrose

 

Differentiation at a Glance

Feature	Delirium Tremens (DT)	Hepatic Encephalopathy (HE)	Mixed (DT + HE)
Onset	12–72 h after last drink	Insidious or precipitant-driven	Variable; overlap possible
Autonomic	Prominent (diaphoresis, tachycardia, hypertension)	Mild or absent	Prominent (DT drives autonomic)
Tremor	Coarse, whole-body	Asterixis (flap)	Both may coexist
Fever	Common (low-grade to 39°C)	Suggests sepsis trigger	Present; exclude infection
Seizures	Yes (early, tonic-clonic)	Rare; suggests other cause	Risk amplified
Pupils	Dilated, reactive	Normal to small	May be dilated
EEG	Low-voltage fast activity	Triphasic waves	May show both patterns
Ammonia	Normal	Elevated (correlates poorly)	Elevated
CIWA-Ar	Scores high	Does not apply	Apply cautiously; titrate carefully
First-Line Rx	Benzodiazepines (IV lorazepam)	Lactulose ± rifaximin	Treat DT first; titrate HE therapy
Key Pitfall	Under-treatment → death	BZDs worsen HE	BZD + HE: titrated phenobarbital safer

 

11. References

1.       DeCarolis DD, Rice KL, Ho L, Willenbring ML, Cassaro S. Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit. Pharmacotherapy. 2007;27(4):510–8.

2.       Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109–13.

3.       Hsieh MJ, Lee WC, Chao YC, Lin MC, Chen CW, Tang YH, et al. Risk factors for alcohol withdrawal delirium: a systematic review and meta-analysis. Drug Alcohol Depend. 2021;224:108753.

4.       Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the AASLD and EASL. Hepatology. 2014;60(2):715–35.

5.       Ferenci P. Hepatic encephalopathy. Gastroenterol Rep. 2017;5(2):138–47.

6.       Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(4):235–46.

7.       Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: a systematic review. Ind Psychiatry J. 2013;22(2):100–8.

8.       Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother. 2011;45(5):649–57.

9.       Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis. Hepatology. 2007;45(6):1348–54.

10.     Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7(9):515–25.

11.     Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353–7.

12.     Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med. 2015;88(3):247–56.

13.     Nanchal R, Subramanian R, Karvellas CJ, Bhupinderjit SR, Balk EM, Bihari S, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU. Crit Care Med. 2020;48(3):e173–91.

14.     Nguyen NH, Khera R, Singh S, Bhatt DL, Bhatt L, Anand BS. Annual burden and costs of hospitalization for alcohol-related liver disease and alcohol withdrawal in the United States. Clin Gastroenterol Hepatol. 2019;17(10):2040–7.

15.     Philips CA, Ahamed R, Augustine P. Hepatic encephalopathy with concurrent alcohol withdrawal: a diagnostic and therapeutic challenge. World J Gastroenterol. 2021;27(3):244–56.